Cell Source Stock Probability of Future OTC Stock Price Finishing Over 17.16
| CLCS Stock | USD 0.43 0.14 24.56% |
Cell |
Cell Source Target Price Odds to finish over 17.16
The tendency of Cell OTC Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over $ 17.16 or more in 90 days |
| 0.43 | 90 days | 17.16 | close to zero percent |
Based on a normal probability distribution, the odds of Cell Source to move over $ 17.16 or more in 90 days from now is close to zero percent (This Cell Source probability density function shows the probability of Cell OTC Stock to fall within a particular range of prices over 90 days) . Probability of Cell Source price to stay between its current price of $ 0.43 and $ 17.16 at the end of the 90-day period is about 50.0 .
Given the investment horizon of 90 days Cell Source has a beta of 0.0735 suggesting as returns on the market go up, Cell Source average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Cell Source will be expected to be much smaller as well. Moreover Cell Source has an alpha of 1.2219, implying that it can generate a 1.22 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Cell Source Price Density |
| Price |
Predictive Modules for Cell Source
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Cell Source. Regardless of method or technology, however, to accurately forecast the otc stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the otc stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Cell Source's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Cell Source Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Cell Source is not an exception. The market had few large corrections towards the Cell Source's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Cell Source, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Cell Source within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 1.22 | |
β | Beta against Dow Jones | 0.07 | |
σ | Overall volatility | 0.13 | |
Ir | Information ratio | 0.07 |
Cell Source Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Cell Source for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Cell Source can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Cell Source is way too risky over 90 days horizon | |
| Cell Source has some characteristics of a very speculative penny stock | |
| Cell Source appears to be risky and price may revert if volatility continues | |
| Cell Source currently holds 6.5 M in liabilities. Cell Source has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Cell Source until it has trouble settling it off, either with new capital or with free cash flow. So, Cell Source's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Cell Source sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Cell to invest in growth at high rates of return. When we think about Cell Source's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (5.47 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Cell Source currently holds about 93.09 K in cash with (3.38 M) of positive cash flow from operations. | |
| Roughly 32.0% of the company shares are held by company insiders |
Cell Source Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Cell OTC Stock often depends not only on the future outlook of the current and potential Cell Source's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Cell Source's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 29.1 M | |
| Short Long Term Debt | 6.5 M | |
| Cash And Short Term Investments | 93.1 K | |
| Shares Float | 24.5 M |
Cell Source Technical Analysis
Cell Source's future price can be derived by breaking down and analyzing its technical indicators over time. Cell OTC Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Cell Source. In general, you should focus on analyzing Cell OTC Stock price patterns and their correlations with different microeconomic environments and drivers.
Cell Source Predictive Forecast Models
Cell Source's time-series forecasting models is one of many Cell Source's otc stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Cell Source's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the otc stock market movement and maximize returns from investment trading.
Things to note about Cell Source
Checking the ongoing alerts about Cell Source for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Cell Source help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Cell Source is way too risky over 90 days horizon | |
| Cell Source has some characteristics of a very speculative penny stock | |
| Cell Source appears to be risky and price may revert if volatility continues | |
| Cell Source currently holds 6.5 M in liabilities. Cell Source has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Cell Source until it has trouble settling it off, either with new capital or with free cash flow. So, Cell Source's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Cell Source sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Cell to invest in growth at high rates of return. When we think about Cell Source's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (5.47 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Cell Source currently holds about 93.09 K in cash with (3.38 M) of positive cash flow from operations. | |
| Roughly 32.0% of the company shares are held by company insiders |
Additional Tools for Cell OTC Stock Analysis
When running Cell Source's price analysis, check to measure Cell Source's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cell Source is operating at the current time. Most of Cell Source's value examination focuses on studying past and present price action to predict the probability of Cell Source's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cell Source's price. Additionally, you may evaluate how the addition of Cell Source to your portfolios can decrease your overall portfolio volatility.